

Universal Biosensors Inc
ARBN 121 559 993

1 Corporate Avenue
Rowville VIC 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

26 July 2017

Universal Biosensors, Inc. – H1 2017 Results Conference Call & Webcast

Melbourne, Australia, 26 July 2017: Universal Biosensors, Inc. (ASX: UBI) will be hosting an investor call to present their First Half 2017 financial results on Monday 7 August 2017 at 11:00AM AEST.

The call will be hosted by Universal Biosensors Interim Chief Executive Officer, Andrew Denver.

Investors are invited to register for the live webcast of the Half Year results via the following link:

<http://webcasting.boardroom.media/broadcast/59752b03aab2325cc3341e38>

The webcasting will be recorded and can be accessed via the above link following the presentation.

Investors can access the call by phone through the dial in details below:

Conference ID: 314357

Dial in details:

Australia Toll Free 1 800 558 698
Alternate Australia Toll Free 1 800 809 971
Australia Local Number +612 9007 3187
New Zealand 0800 453 055
China Wide 4001 200 659
Singapore 800 101 2785
Hong Kong 800 966 806
United Kingdom 0800 051 8245
United States 1855 8811 339

Ends

Enquiries:

Mr. Salesh Balak
Mr. Andrew Denver
+61 3 9213 9000

Rebecca Wilson (WE Buchan) 0417 382 391

Universal Biosensors Inc
ARBN 121 559 993

1 Corporate Avenue
Rowville VIC 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



Universal Biosensors

About Universal Biosensors

For additional information regarding Universal Biosensors, refer to: <http://www.universalbiosensors.com/>.

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.